The experts who make up the Urologic Oncology Program at Rutgers Cancer Institute are keenly focused on providing care that meets the unique needs of each individual. We provide highly specialized and compassionate care for patients with tumors of genitourinary tract. To request an appointment, call 844-CANCERNJ.
Our team offers an unparalleled level of expertise and comprehensive services committed to improving patient outcomes in a comfortable and enriching environment. Our physicians specialize in the diagnosis and treatment of tumors of the prostate, testis, kidney, and bladder.
Rutgers Cancer Institute is a leader in laparoscopic renal procedures and robotic surgery and has extensive experience performing robotic prostatectomies – our urologic oncologists have performed more than 1,500 robotic radical prostatectomies and more than 600 partial and/or radical nephrectomies in the past 5 years. Nearly 150 radical cystectomies are performed annually at our center.
Our Prostate Cancer Program provides a hub for basic and clinical research in prostate cancer as well as a forum for prostate cancer outreach.
The Latest Diagnostic and Treatment Options
Rutgers Cancer Institute and Robert Wood Johnson University Hospital provides access to the latest technological advancements for prostate and bladder cancer, including the most comprehensive clinical trial portfolio for genitourinary cancers in the state of New Jersey.
Blue Light Cystoscopy
The Urologic Oncology Program at Rutgers Cancer Institute and Robert Wood Johnson University Hospital offers blue light cystoscopy with Cysview® to help improve detection of certain bladder cancers. Cysview is an optical imaging agent that makes non-muscle invasive bladder cancer glow bright pink in blue light, enabling urologists to better see and remove tumors with greater accuracy.
Jelmyto Treatment for Upper Urinary Tract Urothelial Cancer
Jelmyto is a brand of mitomycin gel, which is a reverse thermal hydrogel that has the chemotherapeutic drug, mitomcyin in it. It has been a standard in the management of non-muscle invasive urothelial carcinoma of the bladder for some time, and recently was innovated to effectively treat the kidneys and other upper tract disease.
Additional Treatments
- MRI with Ultrasound Fusion Prostate Biopsy
- Single-Port and Multi-Port Robotic Surgery
Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, earned several High Performing ratings in the 2023-2024 U.S. News & World Report Best Hospitals survey, including for prostate cancer surgery. In fact, University Hospital was 1 of 4 New Jersey hospitals afforded this designation.
Rutgers Cancer Institute was also designated a Testicular Cancer Center of Excellence by the Testicular Cancer Awareness Foundation and the Testicular Cancer Resource Center, which are two leading testicular cancer organizations in the U.S.
To request an appointment, call 844-CANCERNJ. | Find Urologic Oncology Clinical Trials.
Your Urologic Oncology Team
- Medical Oncologist
- Associate Professor, Rutgers Robert Wood Johnson Medical School
- Medical Oncologist
- Medical Director, Office of Human Research Subjects, Rutgers Cancer Institute
- Associate Professor of Medicine, Division of Medical Oncology, and Section of Solid Tumor, Rutgers Robert Wood Johnson Medical School
- Medical Oncologist
- Assistant Professor of Medicine
- Urologic Oncologist
- Director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute
- Assistant Professor of Surgery, Rutgers Robert Wood Johnson Medical School
- Chief of Urologic Oncology, Rutgers Cancer Institute
- Program Director, Urology Residency Program, Rutgers Robert Wood Johnson Medical School
- Professor, Rutgers Robert Wood Johnson Medical School
- Urologic Oncologist
- Associate Professor, Department of Surgery and Division of Urology at Rutgers Robert Wood Johnson Medical School
- Director of Clinical and Translational Research in Urologic Oncology
- Urologic Oncologist
- Medical Director, Clinical Network for Radiation Oncology
- Radiation Oncologist
- Radiation Oncologist
- Associate Professor of Radiation Oncology and Division of Clinical Radiation Oncology,
- Rutgers Robert Wood Johnson Medical School
- Director of Brachytherapy, Department of Radiation Oncology
- Medical Director, Laurie Proton Therapy Center
- Radiation Oncologist
- Professor of Radiation Oncology, Rutgers Robert Wood Johnson Medical School
- Advanced Practice Provider
- Advanced Practice Provider
- Advanced Practice Nurse
- Advanced Practice Nurse
- Physician Assistant
- Advanced Practice Provider
- Advanced Practice Provider
- Advanced Practice Nurse
- Nurse Clinician
Useful Links to our Resource & Learning Center
Related Articles and Press
Optimizing TURBT: Balancing Surgical Skill and Advanced Technology - Vignesh Packiam & Mark Tyson
Listen in as Dr. Vignesh Packiam discusses optimizing TURBT with UroToday.
Rethinking Risk: When to Repeat TURBT in Complex Bladder Cancer Cases
At the American Urological Association 2025 Annual Meeting, an expert panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology, weighing the benefits and limitations of repeat TURBT, the use of blue light cystoscopy, and the implications for intravesical therapy, early cystectomy, or systemic treatment in light of emerging data and evolving risk stratification.
Check Yourself: Why Being Proactive About Testicular Cancer Matters
Testicular cancer is highly treatable, especially when caught early, making awareness and self-exams essential. That’s why it’s crucial for young men to know the warning signs and take charge of their health. Dr. Thomas Jang shares more.
Top 5 Facts to Know About Kidney Cancer
Kidney cancer, also known as renal cell carcinoma or RCC, forms when healthy cells in one or both kidneys grow out of control. Learn more with Dr. Saum Ghodoussipour.
Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC
Vignesh T. Packiam, MD, and Katie S. Murray, DO, MS, weigh multiple recent studies that explore the efficacy of gemcitabine/docetaxel as a frontline therapy for upper tract urothelial carcinoma, highlighting its potential as an alternative to BCG amid supply shortages and its promising outcomes in preserving kidney function.
Blue Light Cystoscopy for Bladder Cancer
Learn more about how blue light cystoscopy is used to help patients with bladder cancer with Dr. Vignesh T. Packiam.
Oncologist Shares Tips for Kidney Health
Dr. Thomas L. Jang shares tips for keeping your kidneys healthy and preventing kidney cancer.
Testicular Cancer: It’s Time to Talk About it
According to data from the National Cancer Institute, the median age of a cancer diagnosis is 66 years, but certain cancers occur more commonly in young people. Dr. Thomas L. Jang shares more.
5 Tips to Boost Bladder Health
While researchers are working to better understand the causes of bladder cancer, there a number of things impacting bladder health that can be controlled with a lifestyle adjustment. Dr. Saum Ghodoussipour shares more.